This week we have two fantastic interviews for you: The first is with Dr. Ben Mazer on the interplay between social media and news; the second is with Dr. Tem Bendapudi on whether Caplacizumab should be the standard of care for thrombotic thrombocytopenic purpura (TTP).

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

Download our free app to listen on your phone